Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Fulvestrant Superior to Anastrozole in Extending Progression-Free Survival in Patients with Breast Cancer

TON - September 2016, Vol 9, No 5 - Breast Cancer
Sophie Granger

In patients with hormone receptor (HR)-positive, locally advanced or metastatic breast cancer, treatment with fulvestrant (Faslodex) demonstrated superiority over anastrozole (Arimidex) in achieving extended progression-free survival, according to a recent press release from AstraZeneca.

This information comes from the primary end point results of the randomized, double-blind, phase 3 FALCON (Fulvestrant and Anastrozole Compared in Hormonal Therapy Naïve Advanced Breast Cancer) trial, which is an ongoing study comparing the effects of fulvestrant 500 mg and anastrozole 1 mg on disease progression in women with HR-positive locally advanced or metastatic breast cancer who have not received previous hormonal treatment. The adverse event profile was largely consistent with the current safety profile of these drugs.

Currently, aromatase inhibitors (eg, anastrozole) are standard of care for this patient population.

“The FALCON results bring us closer to offering more and earlier treatment options to postmenopausal women with HR-positive locally advanced or metastatic breast cancer; the potential to delay disease progression is important for these patients as there is currently no cure,” stated Sean Bohen, MD, PhD, Chief Medical Officer, AstraZeneca, in the press release.

A full evaluation of FALCON trial data is still being conducted, with results expected to be presented later in 2016.

Source: AstraZeneca’s Faslodex Met Primary Endpoint in First-Line Treatment of Advanced Breast Cancer [news release]. London, United Kingdom: AstraZeneca; May 27, 2016. www.astrazeneca.com/media-centre/press-releases/ 2016/astrazenecas-faslodex-met-primary-endpoint-in-first-line-treatment-of-advanced-breast-cancer.html. Accessed June 1, 2016.

Related Items
MONALEESA-7 Sets New Standard of Care for Premenopausal Women with Advanced Breast Cancer
Phoebe Starr
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in Breast Cancer
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in Breast Cancer, Drug Updates, FDA Approvals
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Yvette Florio Lane
Web Exclusives published on May 14, 2019 in Breast Cancer, FDA Approvals, In the News
FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer
Yvette Florio Lane
Web Exclusives published on April 5, 2019 in Breast Cancer, FDA Approvals, In the News
Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness
Yvette Florio Lane
Web Exclusives published on April 1, 2019 in Breast Cancer, FDA Approvals, In the News
5 mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer
Phoebe Starr
TON - February 2019, Vol 12, No 1 published on March 1, 2019 in Breast Cancer
Weight-Loss Intervention in Women with Breast Cancer Works Only with Adherence
Phoebe Starr
TON - February 2019, Vol 12, No 1 published on March 1, 2019 in Breast Cancer
Omega-3 Fatty Acids Significantly Reduced Pain in Obese Patients with Breast Cancer
Meg Barbor, MPH
TON - November 2018, Vol 11, No 5 published on November 28, 2018 in Breast Cancer
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Breast Cancer
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Breast Cancer
Last modified: September 14, 2016